摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-Aminobenzamido)-5-hydroxynaphthalene-2-sulfonic acid | 6268-29-7

中文名称
——
中文别名
——
英文名称
4-(4-Aminobenzamido)-5-hydroxynaphthalene-2-sulfonic acid
英文别名
4-[(4-aminobenzoyl)amino]-5-hydroxynaphthalene-2-sulfonic acid
4-(4-Aminobenzamido)-5-hydroxynaphthalene-2-sulfonic acid化学式
CAS
6268-29-7
化学式
C17H14N2O5S
mdl
——
分子量
358.4
InChiKey
OZLAQSWQXWKDMI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    138
  • 氢给体数:
    4
  • 氢受体数:
    6

文献信息

  • Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same
    申请人:Shapiro Robert
    公开号:US20070032418A1
    公开(公告)日:2007-02-08
    Lead compounds were obtained in a high throughput screen (HTS) of angiogenin (ANG; a potent inducer of angiogenesis) enzyme activity, an RNase. One lead was shown to delay appearance of tumors in an animal tumor system, and to reduce the number of animals having tumors. Several lead compound analogs were found to be even more potent inhibitors of ANG activity compared to the original leads, and two were also found to have greater affinity for ANG than for pancreatic RNase. Other embodiments disclose a method comprising obtaining a ribonuclease inhibitor and a composition; and admixing the ribonuclease inhibitor and the composition to form an admixture, wherein a ribonuclease that may be present in the admixture is inhibited.
  • US4216165A
    申请人:——
    公开号:US4216165A
    公开(公告)日:1980-08-05
  • US7264932B2
    申请人:——
    公开号:US7264932B2
    公开(公告)日:2007-09-04
  • [EN] SMALL MOLECULE INHIBITORS THAT BLOCK ASSEMBLY OF THE TGF-BETA SIGNALING COMPLEX<br/>[FR] INHIBITEURS À PETITES MOLÉCULES QUI BLOQUENT L'ASSEMBLAGE DU COMPLEXE DE SIGNALISATION DE TGF-BÊTA
    申请人:UNIV TEXAS
    公开号:WO2011094749A2
    公开(公告)日:2011-08-04
    A method of treating fibrotic disorders or cancer in a subject comprises administering to a subject who would benefit from such treatment a therapeutically effective amount of one or more TGF-β inhibitors. Methods for screening for compounds that inhibit assembly of the TGF-β ternary complex are also disclosed.
查看更多